Biotech

All Articles

Vaxcyte rises on 'stunning' 31-valent PCV win against Pfizer

.Vaxcyte introduced what analysts referred to as "spectacular" phase 1/2 data for its 31-valent pneu...

Recursion's human brain ailment trial presents little proof of effectiveness

.Recursion has discovered via an early test of its tech-enabled method to medicine exploration, disc...

Acepodia, Pfizer click on all together for chemistry-based cell therapy

.Call it a situation of great chemistry: Acepodia, a biotech based upon Nobel Champion scientific re...

Praxis epilepsy medicine reduces confiscations in stage 2 litigation

.Practice Accuracy Medicines has racked up yet another midphase gain in epilepsy this year, along wi...

Three execs surrender as Dyne messages combined data for DMD applicant

.After leaving a professional grip many years back, Dyne Therapeutics has actually uncovered new per...

Arrowhead fires off stage 3 data in rare metabolic ailment ahead of market clash with Ionis

.Arrowhead Pharmaceuticals has revealed its own give before a potential face-off with Ionis, posting...

Pfizer, Valneva present lyme ailment try reliable for second enhancer

.Pfizer and also Valneva might possess about pair of more years to hang around prior to they help ma...

Fierce Biotech Editor-in-Chief Ayla Ellison Speaks Patronize Michelle Benz on the Future of Biotech.

.Allow's study a chat along with Ayla Ellison, Strong Biotech Managing Editor and also Michelle Benz...

New information show how Bayer's asundexian fell short to prevent strokes

.Bayer put on hold the period 3 trial for its variable XIa prevention asundexian late in 2015 after ...

Sanofi's tolebrutinib falls short 2 of 3 late-stage MS trials

.Sanofi is still bented on taking its several sclerosis (MS) med tolebrutinib to the FDA, managers h...